SENS Earnings Prediction
The chart below shows how SENS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SENS sees a +7.21% change in stock price 10 days leading up to the earnings, and a -13.28% change 10 days following the report. On the earnings day itself, the stock moves by +0.11%. This data can give you a slight idea of what to expect for the next quarter's release.
SENS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
8.30M
3.33%
94.63%
Gross Margin
47.62%
251.18%
-150.11%
Operating Margin
-172.00%
-18.78%
-67.91%
Net Margin
-186.53%
-12.86%
-66.83%
EPS
-0.02
-33.33%
-50.00%
No Data Available
SENS Earnings Analysis
Senseonics Holdings Inc Corporation (SENS.A) Earnings Conference Call
Positive
Earnings Surprise Report: Senseonics Holdings, Inc. beats earnings expectations with reported EPS of $-0.02, exceeding expectations of $-0.03.
Continuous Glucose Monitor Approval: The US approval of Eversense 365, the world’s first and only once yearly continuous glucose monitor, marks a significant milestone for the company.
Positive Feedback on Eversense 365: Positive reception and feedback from both providers and patients regarding Eversense 365 since its launch in November.
CE Mark Approval Plans: The company has filed for CE Mark approval for Eversense 365, with plans for a European launch in the second half of 2025.
Patient Base Expansion: The patient base increased by 56% to approximately 6,000 global patients, exceeding the target growth of 50%.
Eversense Prescriber Growth: The number of annual US Eversense prescribers increased by 73% to over 2,400, indicating strong market interest.
Direct-to-Consumer Lead Surge: Direct-to-consumer leads increased by 40% compared to 2023, with average monthly leads more than doubling after the launch of Eversense 365.
Patient Base Transition: Approximately 81% of the patient base switched from other CGMs, demonstrating strong competitive positioning.
Gross Profit Surge: The gross profit for Q4 2024 was $4 million, significantly up from $1.1 million in the prior-year period, driven by increased margins on the 365-day product.
2025 Revenue Projections: The company expects full year 2025 global net revenue to be approximately $34 million to $38 million, reflecting growth potential as they transition US patients to Eversense 365.
Negative
Increased Net Loss: Net loss increased by $18.2 million in 2024 compared to 2023, primarily due to a reduction in gains from the exchange of existing notes and changes in the fair value of derivatives.
Gross Profit Decline: Gross profit for 2024 was only $0.5 million, a decrease from $3.1 million in 2023, largely due to $4.8 million in one-time charges related to the transition from Eversense E3 to Eversense 365.
SG&A Expense Increase: Selling, general and administrative expenses increased by $4.3 million year-over-year to $34.2 million, driven by personnel costs, consulting fees, sales commissions, and legal expenses.
Patient Growth vs. Revenue Stagnation: Despite a 56% increase in patient base, total revenue remained relatively flat at $22.5 million in 2024 compared to $22.4 million in 2023, indicating challenges in converting patient growth into revenue.
Cash Utilization Forecast: The company expects cash utilization in 2025 to be between $50 million and $60 million, indicating a significant cash burn as they transition to the new product.
Gross Profit Margin Outlook: The gross profit margin for the full year 2024 would be more than 16% excluding one-time product transition costs, which is relatively low for a medical device company.
Impact of Patient Assistance Programs: The company anticipates a noticeable impact on average selling price and revenue in the first half of 2025 due to patient assistance programs, which may affect profitability.
SENS FAQs
How does SENS typically perform around its earnings report dates?
Is Senseonics Holdings Inc (SENS) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SENS Earning Call Sentiment
Senseonics Holdings, Inc. (AMEX:SENS) Q4 2024 Earnings Call Transcript
SENS.A
1.34%Positive
The earnings call presents a mixed picture with financial risks and market adoption challenges overshadowing positive developments. While there is growth in US revenue and improved gross profit margins, the company faces significant net losses and declining international revenue. The absence of a shareholder return plan and unclear responses about reimbursement efforts further contribute to uncertainty. Despite optimism around new product launches and collaborations, the overall sentiment leans negative due to financial instability and market adoption risks.
